Australia's Mayne Pharma gets approval to market anti-cancer drug in Germany


Mayne PharmaSYDNEY (AFX) - Mayne Pharma Ltd said it has received approval to market its version of the anti-cancer drug oxaliplatin in Germany.

The pharmaceutical company said Germany's oxaliplatin market is one of the largest, with a local market value (LMV) of 88 mln usd.

Mayne now has marketing approval for its oxaliplatin in 13 European Union countries as well as Australia.

In May 2006, the High Court in the UK ruled in favour of Mayne Pharma in relation to patents for its oxaliplatin products.

Additionally, a German court has ruled that the process used to manufacture the active ingredient used in Mayne Pharma's oxaliplatin products does not infringe the patents in issue.

Sanofi-Aventis SA has appealed both the UK and German rulings.



Previous entry: Bright idea of sticky plaster that can beat skin cancer

Next entry: End sick crusade against breast cancer research

Find recent content on the main index or look in the archives to find all content.